GCM
AVIR icon

Gladius Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Gladius Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,491
Closed -$28.4K – 89
2024
Q3 		$28.4K Sell
8,491
-337
-4% -$1.22K ﹤0.01% 239
2024
Q2 		$29.2K Buy
8,828
+288
+3% +$1.07K ﹤0.01% 275
2024
Q1 		$34.5K Buy
+8,540
New +$33.4K 0.01% 268
2023
Q4 		– Sell
-8,581
Closed -$25.7K – 322
2023
Q3 		$25.7K Buy
8,581
+4,251
+98% +$14.5K ﹤0.01% 327
2023
Q2 		$16.2K Sell
4,330
-3,383
-44% -$12.7K ﹤0.01% 312
2023
Q1 		$25.8K Sell
7,713
-200
-3% -$811 ﹤0.01% 306
2022
Q4 		$38.1K Buy
7,913
+3,064
+63% +$15.5K ﹤0.01% 236
2022
Q3 		$28K Buy
+4,849
New +$37.1K ﹤0.01% 314

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Gladius Capital Management's AVIR Position: Q4 2024 in Review

Gladius Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2024, closing a stake of 8,491 shares — an estimated $28.4K sold.

Gladius Capital Management first reported a position in AVIR in Q3 2022 and held it in 8 quarters. The position peaked at $38.1K in Q4 2022. 106 funds tracked by Wall St. Rank hold AVIR as of Q4 2024.

  • Gladius Capital Management reported no remaining Atea Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Gladius Capital Management sold 8,491 Atea Pharmaceuticals shares in Q4 2024, an estimated $28.4K.
  • Gladius Capital Management first reported a position in Atea Pharmaceuticals in Q3 2022 and held it in 8 quarters.
  • Gladius Capital Management's Atea Pharmaceuticals position peaked at $38.1K in Q4 2022.
  • 106 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2024.

Based on Gladius Capital Management's 13F filing for Q4 2024, filed 31 Jan 2025.